These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17539942)

  • 1. Awareness of potential valvulopathy risk with pergolide and changes in clinical practice after label change: a survey among European neurologists.
    Lledó A; Dellva MA; Strombom IM; Wilkie JL; Jungemann ME; Royer MG; Simmons VE; Cavazzoni PA
    Eur J Neurol; 2007 Jun; 14(6):644-9. PubMed ID: 17539942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac valvulopathy associated with pergolide use.
    Zadikoff C; Rochon P; Lang A
    Can J Neurol Sci; 2006 Feb; 33(1):27-33. PubMed ID: 16583718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
    Corvol JC; Schüpbach M; Bonnet AM;
    Rev Neurol (Paris); 2005 Jul; 161(6-7):637-43. PubMed ID: 16141947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease.
    Dewey RB; Reimold SC; O'Suilleabhain PE
    Arch Neurol; 2007 Mar; 64(3):377-80. PubMed ID: 17353380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 9. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists.
    Simonis G; Fuhrmann JT; Strasser RH
    Mov Disord; 2007 Oct; 22(13):1936-42. PubMed ID: 17659636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey on general knowledge on Parkinson's disease in patients with Parkinson's disease and current clinical practice for Parkinson's disease among general neurologists from Southwest China.
    Li J; Chen D; Song W; Chen K; Cao B; Huang R; Yang R; Shang H
    Clin Neurol Neurosurg; 2014 Mar; 118():16-20. PubMed ID: 24529223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pergolide associated cardiac valvulopathy based on Ontario administrative data.
    Zadikoff C; Duong-Hua M; Sykora K; Marras C; Lang A; Rochon P
    Can J Neurol Sci; 2008 May; 35(2):173-8. PubMed ID: 18574930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's drugs linked to heart valve trouble.
    Harv Heart Lett; 2007 Apr; 17(8):7. PubMed ID: 17402160
    [No Abstract]   [Full Text] [Related]  

  • 14. Valvular health disease with pergolide.
    Prescrire Int; 2003 Dec; 12(68):225. PubMed ID: 14986695
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine agonists and the risk of cardiac-valve regurgitation.
    Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
    N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
    Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
    J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use].
    van Strater AC; Bax JJ; van Hilten JJ; Jukema JW
    Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
    Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G
    J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pergolide mesylate in Parkinson's disease treatment.
    Pezzoli G; Canesi M; Pesenti A; Mariani CB
    J Neural Transm Suppl; 1995; 45():203-12. PubMed ID: 8748627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.